Hikma Pharmaceuticals (HKMPF) is in talks with partners across the world to prepare to sell a generic version of Ozempic and Wegovy, as patents on Novo Nordisk’s (NVO) diabetes and weight loss ...

Shares of Hikma Pharmaceuticals stock opened at GBX 2,123.65 ($27.45) on Friday. The stock has a market capitalization of £5.89 billion, a P/E ratio of 20.84, a PEG ratio of 2.38 and a beta of 0.41.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Drugmaker Hikma is in talks with partners across the world to prepare to sell a generic version of Ozempic ...

Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the ...

Axsome Therapeutics AXSM announced that it has entered into a settlement agreement with Hikma Pharmaceuticals related to patents for its narcolepsy drug, Sunosi (solriamfetol). The settlement ...

Dividend amount and dividend per share are quoted in the currency of the stock selected. Please note that past performance is not a reliable indicator of future returns. Important Information Please ...

Amman, Jordan: Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, today reports its audited results for the year ended 31 December 2024. The Group reported revenue growth of 9% (9% ...

"Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut ...

Investing.com -- Shares of Hikma Pharmaceuticals (LON:HIK) fell over 5% on Wednesday following its FY24 results, as core operating profits and weaker-than-expected margins failed to meet investor ...

(Alliance News) - Hikma Pharmaceuticals PLC on Wednesday said it planned to increased spending on research and development to support further growth after reporting strong annual results.

The margin also softened, to 22.8% from 24.6% in 2023. As at 0830 GMT, shares in Hikma were down 8% at 2,122p. Riad Mishlawi, chief executive, insisted it had been "another strong year" for the ...